SEC Form 4 · accession 0000874015-17-000067
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Klein III
Director
Period of report
Nov 15, 2017
Accepted (ET)
Nov 17, 2017 · 5:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 15, 2017 | M | 2,250 | $28.47 | A | 9,377 | D | |
| Common StockF1 | Nov 15, 2017 | S | 2,250 | $53.56 | D | 7,127 | D | |
| Common StockF1 | Nov 16, 2017 | M | 2,812 | $12.94 | A | 9,939 | D | |
| Common Stock | holding | — | — | — | 100 | I | By son |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Employee Director Stock Option (right to buy) | $28.47 | Nov 15, 2017 | M | 2,250 | D | Jul 1, 2017 | Jun 30, 2023 | Common Stock | 2,250 | 9,000 | D |
| Non-Employee Director Stock Option (right to buy) | $12.94 | Nov 16, 2017 | M | 2,812 | D | Jul 2, 2016 | Jul 1, 2022 | Common Stock | 2,812 | 0 | D |
Explanation of responses
- F1Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017.